RxDoctor Payments DataLook up a doctor →

William Cragun, MD

Dermatology · San Antonio, TXNPI 1578673166

Payments from drug & device makers

$2,261,905in general payments, 2019–2025

Across 3,554 payments — averaging $636.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$533K
  • Johnson & Johnson$298K
  • Lilly USA, LLC$272K
  • E.r. Squibb & Sons, L.L.C.$189K
  • Janssen Scientific Affairs, LLC$172K
  • Galderma Laboratories, L.p.$158K
  • plus $640K from 38 others

What the payments were for

  • Consulting fees$266,54912%
  • Speaking & faculty fees$1,630,68976%
  • Travel & lodging$188,9599%
  • Food & beverage$65,6833%
  • Education$1,0290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,261,905 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$987,383
Medicare patients
731
Services billed
14,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$212,094
Taltz AutoinjectorIxekizumab16$196,185
Dupixent PenDupilumab50$187,241
OtezlaApremilast16$103,085
Cosentyx Sensoready (2 Pens)Secukinumab14$101,176
Tacrolimus32$4,316
Clobetasol Propionate94$4,238
Calcipotriene18$2,332
Metronidazole41$1,934
Doxycycline Hyclate52$1,712
Fluorouracil26$1,355
Ketoconazole76$1,089
Triamcinolone Acetonide94$1,045
Hydrocortisone80$941
Terbinafine Hcl43$807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$425$103,08516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.

Other dermatology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →